Methods of treating ttr amyloidosis using ag10
AssigneeEidos Therapeutics, Inc.
InventorsUma Sinha, Satish Rao
Life of this patent
Estimating the term…
Abstract
Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.
Claims30
A method of treating transthyretin (TTR) amyloidosis in a subject in need thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount of Compound 1, having the formula:
- or a pharmaceutically acceptable salt thereof, wherein said therapeutically effective amount is a total daily dosage of about 10 mg to 2,000 mg.
-4. (canceled)
A method of treating transthyretin (TTR) amyloidosis in a subject in need thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount of Compound 1, having the formula:
- or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount of Compound 1 maintains a trough blood plasma concentration of Compound 1 of at least 5 μM.
-23. (canceled)
-34. (canceled)
-39. (canceled)
-55. (canceled)
57-61. (canceled)
65-81. (canceled)
A single unit dosage comprising about 10-1,000 mg of Compound 1, having the formula:
- or a pharmaceutically acceptable salt thereof.
-87. (canceled)
(canceled)
Dependencies are inferred from the claim text.